Correction: Combined inhibition of BCL-2 and MCL-1 overcomes BAX deficiency-mediated resistance of TP53-mutant acute myeloid leukemia to individual BH3 mimetics (Blood Cancer Journal, (2023), 13, 1, (57), 10.1038/s41408-023-00830-w)

Bing Z. Carter, Po Yee Mak, Wenjing Tao, Edward Ayoub, Lauren B. Ostermann, Xuelin Huang, Sanam Loghavi, Steffen Boettcher, Yuki Nishida, Vivian Ruvolo, Paul E. Hughes, Phuong K. Morrow, Torsten Haferlach, Steven Kornblau, Muharrem Muftuoglu, Michael Andreeff

Research output: Contribution to journalComment/debatepeer-review

Abstract

The following acknowledgement was missing from this article. EA is a TRIUMPH Fellow in the CPRIT Training Program (RP210028). The original article has been corrected.

Original languageEnglish (US)
Article number80
JournalBlood cancer journal
Volume13
Issue number1
DOIs
StatePublished - Dec 2023

ASJC Scopus subject areas

  • Hematology
  • Oncology

MD Anderson CCSG core facilities

  • Biostatistics Resource Group

Fingerprint

Dive into the research topics of 'Correction: Combined inhibition of BCL-2 and MCL-1 overcomes BAX deficiency-mediated resistance of TP53-mutant acute myeloid leukemia to individual BH3 mimetics (Blood Cancer Journal, (2023), 13, 1, (57), 10.1038/s41408-023-00830-w)'. Together they form a unique fingerprint.

Cite this